LCP1 and B-cell chronic lymphocytic leukemia: In addition, CLL scRNA-seq reveals transcriptional heterogeneity and uncovers mutated LCP1 and WNK1 as novel CLL drivers (86), they are likely to be novel drug targets for the treatment of CLL.